Skip to content

Effect of Daily versus Intermittent Iron Supplementation on Hematological values in Non Anemic Pregnant women.

Effect of Daily versus Intermittent Iron Supplementation on Hematological and Oxidative stress parameters in non- Anemic Pregnant women- A Randomized control trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/045021
Enrollment
225
Registered
2022-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O00-O9A- Pregnancy, childbirth and the puerperium

Interventions

Intervention1: Biweekly 100mg Iron supplementation: Women allotted into this group will be provided with one blister pack (100mg elemental iron) for a month and will be instructed to take 2 tablets on

Sponsors

SELF
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age of 18 to 35 years Hemoglobin � 11 gm/dl Primigravida or multigravida at 14 -18 weeks of gestation Singleton pregnancy Pregnant women who are willing to come for follow up antenatal care and deliver in IGMCRI

Exclusion criteria

Exclusion criteria: History of Diabetes Mellitus, Hypertension, Thyroid Disorder History of any hematological disorders Previous history of any blood transfusion Multifetal gestation Smoking and drug abuse Parity more than 3 Previous history of LSCS Previous history of placenta previa, abruptio placenta Chronic illness like liver disease, renal disease, Tuberculosis, heart disease Bleeding piles, chronic peptic ulcer, Gastric intolerance History of hyperemesis Pregnant women who are all under medications like Anti epileptics, thyroid medications, NSAIDs, Anti oxidants.

Design outcomes

Secondary

MeasureTime frame
Oxidative stress parametersTimepoint: 12 weeks

Primary

MeasureTime frame
There will not be significant difference in Hematological parameters in the intervention groups when compared to control group.Timepoint: 12 weeks

Countries

India

Contacts

Public ContactKavitha E

INDIRA GANDHI MEDICAL COLLEGE AND RESEARCH INSTITUTE ,PUDUCHERRY

sabita.kutty@gmail.com9600829655

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026